IRRAS AB Closes Financing Round to Establish IRRAflow™ as Leading CNS Fluid Management Device

May 11, 2016

-Expanding commercialization in Germany and operations in the US to advance flagship technology-

LA JOLLA, Calif. and STOCKHOLM, May 11, 2016 /PRNewswire/ — IRRAS AB, a commercial-stage medical technology company developing breakthrough devices for a broad range of brain pathology therapeutic applications and procedures, today announced the completion of a pivotal round of financing that will support IRRAS’ EU commercial growth strategy and receive regulatory approval in the US to become a global leader in CNS fluid management in the medical device space. The raise totaled SEK $91.25M or $11.25M with participation from Serendipity/Ixora, and The Vandel Group, as well as recognized high net-worth healthcare investors in Sweden.

Read More

©2019
Cerus Advisors
DMCC